Vacina experimental de mRNA demonstra proteção contra múltiplos vírus Ebola

22 de maio de 2026

Reportado por IA

Uma vacina experimental de mRNA demonstrou eficácia contra três cepas do vírus Ebola em testes com roedores. A vacina tem como alvo os vírus Zaire, Sudão e Bundibugyo. Os pesquisadores a desenvolveram em meio a um surto contínuo do vírus Bundibugyo na África.

Yanfeng Yao e seus colegas do Instituto de Virologia de Wuhan criaram a vacina combinando sequências de mRNA para glicoproteínas de cada vírus, juntamente com uma nucleoproteína compartilhada dentro de uma nanopartícula lipídica. Nos testes, camundongos imunizados obtiveram proteção completa contra os vírus Zaire e Sudão e forte proteção contra o Bundibugyo. Hamsters também receberam proteção total contra a exposição ao vírus Sudão.

DNA origami “DoriVac” shows strong immune activation in early tests, offering a potential complement to mRNA vaccines

17 de março de 2026 Reportado por IA Imagem gerada por IA Verificado

Researchers at Harvard’s Wyss Institute and Dana-Farber Cancer Institute report that a DNA origami-based vaccine platform called DoriVac generated robust immune responses in mice and in a human lymph node “Organ Chip” model. The team says the approach could be easier to store and manufacture than lipid nanoparticle–delivered mRNA vaccines, though the work remains preclinical. The results were published in Nature Biomedical Engineering.

Moderna advances hantavirus vaccine after cruise ship deaths

Moderna confirmed ongoing work on an mRNA vaccine for hantavirus following a deadly outbreak on a Dutch cruise ship. The effort, in partnership with Korea University, began in 2023 and shows promise but remains years from completion.

Ebola outbreak declared public health emergency in DRC and Uganda

19 de maio de 2026 Reportado por IA

The World Health Organization has declared a public health emergency over an outbreak of the Bundibugyo strain of Ebola virus in the Democratic Republic of the Congo and Uganda. The move comes as researchers urge faster development of vaccines for lesser-known Ebola strains.

Saúde

Scripps researchers reveal HIV and Ebola weak spots using nanodiscs

Saúde

Scientists discover molecular shredder in deadly parasite

Saúde

AI identifies breast cancer drug for multiple viruses

Uppsala professor warns TBE vaccine may need updating

TBE cases in Sweden have tripled over ten years despite rising vaccinations. Åke Lundkvist, professor of virology at Uppsala University, suspects the virus may have changed, reducing vaccine effectiveness. Researchers are now analyzing 12,000 ticks to investigate.

Egypt targets 140 million annual human vaccine doses by 2030

13 de abril de 2026 Reportado por IA

Egypt's Ministry of Health aims to produce 140 million human vaccine doses annually by 2030 under its Vaccine City project. Health Minister Khaled Abdel Ghaffar reviewed the project's progress, emphasizing efforts for self-sufficiency and exports to regional and international markets.

quinta-feira, 21 de maio de 2026, 04:41h

Vacina experimental de mRNA demonstra proteção contra múltiplos vírus Ebola

Artigos relacionados

DNA origami “DoriVac” shows strong immune activation in early tests, offering a potential complement to mRNA vaccines

Moderna advances hantavirus vaccine after cruise ship deaths

Ebola outbreak declared public health emergency in DRC and Uganda

Scripps researchers reveal HIV and Ebola weak spots using nanodiscs

Scientists discover molecular shredder in deadly parasite

AI identifies breast cancer drug for multiple viruses

Uppsala professor warns TBE vaccine may need updating

Egypt targets 140 million annual human vaccine doses by 2030

Kenya bolsters emergency measures against Ebola

South Africa assesses low risk from new Ebola outbreak

Uganda confirms first Ebola case as 80 deaths reported in DRC

WHO warns of Ebola spread risk as Kenya activates emergency response measures

Scientists warn of bat coronavirus risk in East Africa

Scientists develop antibodies to block widespread Epstein-Barr virus

Scientists uncover cause of rare COVID vaccine blood clots

Stanford scientists develop universal nasal spray vaccine

Este site usa cookies